BC Extra | Dec 7, 2016
Clinical News

GNS identifies disease drivers from CoMMpass data

GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as "top drivers" of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
BC Innovations | Aug 4, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Cyclin dependent kinase 5 (CDK5) In vitro studies suggest inhibiting CDK5 could help prevent metastatic cancers. In cellular models of metastasis and in...
BioCentury | Apr 18, 2011
Strategy

Supercharging Astex

SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company. SuperGen has plenty of cash from...
BC Week In Review | Apr 11, 2011
Company News

Astex Therapeutics, SuperGen deal

SuperGen will acquire fellow cancer company Astex in a cash and stock deal. Astex shareholders will receive $25 million in cash, plus shares that will represent 35% of the combined company's outstanding shares after the...
BC Extra | Apr 8, 2011
Company News

SuperGen to acquire Astex

SuperGen Inc. (NASDAQ:SUPG) will acquire fellow cancer company Astex Therapeutics Ltd. (Cambridge, U.K.) in a cash and stock deal. Astex shareholders will receive $25 million in cash, plus shares that will represent 35% of the...
BC Week In Review | Aug 23, 2010
Clinical News

AT7519: Phase II started

Astex began an open-label, U.S. Phase II trial to evaluate intravenous AT7519 alone or with Velcade bortezomib in up to 30 patients. Millennium Pharmaceuticals Inc. , a subsidiary of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan),...
BioCentury | Nov 16, 2009
Finance

Ebb & Flow

Although the terms of the acquisition of BioTrove Inc. by Life Technologies Corp. (NASDAQ:LIFE) haven't been undisclosed, the transaction could result in a more than 10X return over the next 12 months, according to investor...
BC Week In Review | Apr 20, 2009
Clinical News

AT7519: Phase I data

In a dose-escalation, international Phase I trial in patients with refractory solid tumors, 3.6-34 mg/m 2/day of IV AT7519 inhibited CDK as assessed by a reduction in phospho- nucleophosmin and proliferating cell nuclear antigen (PCNA)...
BC Week In Review | Dec 8, 2008
Clinical News

Astex Therapeutics preclinical data

In mice with MM, AT7519 significantly improved overall survival vs. control (40.0 vs. 27.5 days, p=0.0324). The cyclin dependent kinase (CDK) inhibitor also slowed tumor growth vs. control. Data will be presented at the American...
Items per page:
1 - 10 of 18